A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis is a research paper published in Journal of Clinical Investigation (2023). On theSindex it has a DataRank of 1.2. It has been cited 38 times, with 34 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.550
From this paper's citation signal
Citation Network Contribution
0.623
From 24 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 34 citers.
National Institutes of Health
Grant: AI143965,AI106043,TR003098
AstraZeneca Pharmaceuticals, LP
Grant: ESR-19-20140
Ludwig Family Foundation
Grant: Ludwig scholar grant
National Institutes of Health
Grant: 5UL1TR003098-02
Johns Hopkins Institute for Clinical and Translational Research
National Institutes of Health
Grant: 5K23AI143965-05
Using BTK Inhibitors to Prevent Anaphylactic Drug Reactions
Fields of Study
Keywords